John W Clader

This inventor holds 59 USPTO granted patents and 8 published patent applications and 9 EPO patents, primarily in Gamma Secretase Inhibitors (CPC class 5442). Top assignees: Schering Corporation, Merck Sharp + Dohme Corp., Hoffmann-La Roche Inc.. Active years: 1990-2016.

USPTO Granted Patents = 59 (Patent Applications = 8)

% Patents Active = 76.3

EPO Patents = 9 (Patent Applications = 9)

Average Co-Inventor Count = 4.8

ph-index = 17

Forward Citations = 946(Granted Patents)

Forward Citations (Not Self Cited) = 867(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Millton, VT (US) (2013)
Cranford, NJ (US) (1990 - 2014)
Milton, VT (US) (2011 - 2016)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

1 out of 5,024

Hoffmann-La Roche Inc.

patents

4. 1 out of 1

Pharacopeia Drug Discovery, Inc.

patent

5. 1 out of 28

Schering-Plough Corporation

patents

6. 3 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1990-2016

Loading Chart...

Areas of Expertise:

Gamma Secretase

Azetidinone Compounds

CCR5 Antagonists

Antidiabetic Compounds

MCH Antagonists

Thiochromane

Piperazine Derivatives

Hydroxy-Substituted

Obesity Treatment

Polycyclic Guanine

Muscarinic Antagonists

Phosphodiesterase V

59 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9278965 - Bridged and fused antidiabetic compounds (2016-03-08),

2. 8759337 - Gamma secretase modulators (2014-06-24),

3. 8664411 - Tetrahydropyranochromene gamma secretase inhibitors (2014-03-04),

4. 8569521 - Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors (2013-10-29),

5. 8450343 - Gamma secretase modulators (2013-05-28),

6. 8426403 - Gamma secretase modulators (2013-04-23),

7. 8357682 - Gamma secretase modulators (2013-01-22),

8. 8114879 - Piperazine derivatives useful as CCR5 antagonists (2012-02-14),

9. 8067621 - Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors (2011-11-29),

10. 7998958 - Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors (2011-08-16),

11. RE42461 - Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents (2011-06-13),

12. 7741289 - Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof (2010-06-22),

13. 7732413 - Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof (2010-06-08),

14. 7459442 - Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof (2008-12-02),

15. 7452891 - MCH antagonists and their use in the treatment of obesity (2008-11-18),

Title: The Inventive Journey of John W Clader

Introduction:

John W Clader, a prolific inventor based in Cranford, NJ, has made significant contributions in the field of pharmaceuticals with a remarkable portfolio of 59 patents. His innovative spirit and dedication to improving healthcare have led to groundbreaking inventions that are shaping the future of medicine.

Latest Patents:

Among his latest patents is the development of bridged and fused antidiabetic compounds. These compounds serve as agonists of the G-protein coupled receptor 40 (GPR40), playing a vital role in regulating insulin levels in mammals. The compounds hold promise in the prevention and treatment of Type 2 diabetes mellitus and related conditions such as insulin resistance, obesity, and lipid disorders. Additionally, John W Clader has pioneered gamma secretase modulators, novel compounds that modulate gamma secretase activity and show potential in treating Alzheimer's Disease.

Career Highlights:

Throughout his illustrious career, John W Clader has worked with esteemed pharmaceutical companies such as Schering Corporation and Merck Sharp & Dohme Corporation. His expertise and innovative mindset have led to the development of groundbreaking pharmaceutical compounds that have the potential to revolutionize the healthcare industry.

Collaborations:

Collaboration plays a crucial role in the world of innovation, and John W Clader has had the privilege of working alongside talented individuals like Duane A Burnett and Hubert B Josien. Together, they have synergized their skills and knowledge to drive forward groundbreaking research and development in the field of pharmaceuticals.

Conclusion:

In conclusion, John W Clader stands as a trailblazing inventor whose dedication to innovation and healthcare has resulted in a remarkable portfolio of patents. His groundbreaking work in developing antidiabetic compounds and gamma secretase modulators highlights his commitment to advancing medicine and improving the lives of individuals worldwide. John W Clader's contributions will continue to inspire future generations of inventors and propel the healthcare industry towards new frontiers.